64
IMPACT OF TIME TO SURGERY ON OUTCOMES FOLLOWING LOW ANTERIOR RESECTION FOR RECTAL CANCER
Date
May 18, 2024
BACKGROUND: The objective of this study was to assess the impact of time to surgery (TTS) on outcomes following low anterior resection (LAR) among patients with non-metastatic rectal cancer. Initial treatment approaches were defined as having received upfront surgery (UFS), neoadjuvant chemo-radiation (XRT) or total-neoadjuvant therapy (TNT).
METHODS: The 2004-2017 National Cancer Database was queried for patients with non-metastatic rectal cancer who underwent LAR. TTS was categorized based on the study population’s median TTS from time of diagnosis. We scrutinized the TTS amongst the initial treatment approaches. Kaplan-Meier Method with log-rank test was used to compare and estimate overall survival (OS) rates between patients based on TTS, as well as initial clinical approach. A p-value of < 0.05 was considered statistically significant.
RESULTS: A total of 19,937 patients were identified, of which 44% underwent XRT, 40% UFS, and 16% TNT. For the UFS cohort almost 96% had a TTS ≤ 119 days. Conversely, approximately 77% of both the XRT and TNT cohort has a TTS > 119 days. Data stratified by initial clinical approach and TTS revealed that patients in the UFS + TTS ≤ 119 days cohort experienced a longer median OS compared to their UFS + TTS > 119 days counterparts (151.9 vs. 112.6 months; p = 0.022). Additionally, the UFS + TTS ≤ 119 days cohort was less likely to be lymph node positive (9.9% vs 13.8%; p = 0.025). Among patients who received XRT, the TTS > 119 days cohort was more likely to die within 90-days (2.9% vs 2.0%, p = 0.047) and less likely to achieve 5-year survival (41.7% vs 50.5%, p < 0.001) when compared to their TTS > 119 days counterparts. Furthermore, patients in the TTS > 119 days group were more likely to have pathologic stage IV disease (1.3% vs 1.2%; p = 0.001). Patients in the TNT + TTS ≤ 119 days cohort were more likely to have a small tumor size (0 - 2 cm) on final pathology than their TTS > 119 days counterparts (25.3% vs. 21.3%; p = 0.034). Likewise, the TNT + TTS ≤ 119 days cohort experienced a higher 5-year survival rate (57.6% vs. 49.2%; p > 0.001).
DISCUSSION: Our study demonstrated that across all three clinical approaches TTS > 119 days is associated with poorer outcomes. Consequently, time to surgery may be an important factor to consider in the treatment of patients with non-metastatic rectal cancer who are undergoing LAR.
METHODS: The 2004-2017 National Cancer Database was queried for patients with non-metastatic rectal cancer who underwent LAR. TTS was categorized based on the study population’s median TTS from time of diagnosis. We scrutinized the TTS amongst the initial treatment approaches. Kaplan-Meier Method with log-rank test was used to compare and estimate overall survival (OS) rates between patients based on TTS, as well as initial clinical approach. A p-value of < 0.05 was considered statistically significant.
RESULTS: A total of 19,937 patients were identified, of which 44% underwent XRT, 40% UFS, and 16% TNT. For the UFS cohort almost 96% had a TTS ≤ 119 days. Conversely, approximately 77% of both the XRT and TNT cohort has a TTS > 119 days. Data stratified by initial clinical approach and TTS revealed that patients in the UFS + TTS ≤ 119 days cohort experienced a longer median OS compared to their UFS + TTS > 119 days counterparts (151.9 vs. 112.6 months; p = 0.022). Additionally, the UFS + TTS ≤ 119 days cohort was less likely to be lymph node positive (9.9% vs 13.8%; p = 0.025). Among patients who received XRT, the TTS > 119 days cohort was more likely to die within 90-days (2.9% vs 2.0%, p = 0.047) and less likely to achieve 5-year survival (41.7% vs 50.5%, p < 0.001) when compared to their TTS > 119 days counterparts. Furthermore, patients in the TTS > 119 days group were more likely to have pathologic stage IV disease (1.3% vs 1.2%; p = 0.001). Patients in the TNT + TTS ≤ 119 days cohort were more likely to have a small tumor size (0 - 2 cm) on final pathology than their TTS > 119 days counterparts (25.3% vs. 21.3%; p = 0.034). Likewise, the TNT + TTS ≤ 119 days cohort experienced a higher 5-year survival rate (57.6% vs. 49.2%; p > 0.001).
DISCUSSION: Our study demonstrated that across all three clinical approaches TTS > 119 days is associated with poorer outcomes. Consequently, time to surgery may be an important factor to consider in the treatment of patients with non-metastatic rectal cancer who are undergoing LAR.
Tracks
Related Products
ROBOTIC PORTAL LYMPHADENECTOMY WITH PARTIAL CENTRAL HEPATECTOMY FOR GALLBLADDER CARCINOMA: TECHNIQUE OF VASCULAR HANDLING & HEMOSTASIS IN MINIMALLY INVASIVE APPROACH
Gallbladder carcinoma (GBC) is uncommon and aggressive, generally with poor prognosis…
RIGHT POSTERIOR BILE DUCT INJURY RECONSTRUCTION WITH ROBOTIC RY HEPATICOJEJUNOSTOMY
Right posterior bile duct injury with disconnected duct syndrome creates diagnostic challenges for many endoscopists and radiologists. The diagnosis and treatment are often delayed…
ROBOTIC ANATOMICAL RIGHT HEPATECTOMY FOR NECROTIC CHOLANGIOCARCINOMA
TECHNIQUE OF INFLOW CONTROL IN NAKAMURA TYPE B PORTAL VEIN ANATOMY
Anatomical variations in the inflow vasculatures must be anticipated in any anatomical hepatectomy to avoid complications. Nakamura Type B portal vein (PV) anatomy requires individual isolation of right anterior and posterior PV to avoid narrowing of the left PV…
LAPAROSCOPIC TOTAL PANCREATECTOMY AFTER LAPAROSCOPIC WHIPPLE FOR PANCREATIC DUCTAL ADENOCARCINOMA
Improvements in systemic therapy may increase rate of 2nd novo PDAC after prior PDAC
